• Featured Product
  • KD/KO Validated

PD-L1/CD274 Antibody

PD-L1/CD274 Monoclonal Antibody for FC, IF, IHC, WB, ELISA

Host / Isotype

Mouse / IgG1

Reactivity

human, mouse, pig, rat

Applications

FC, IF, IHC, WB, ELISA

Conjugate

Unconjugated

CloneNo.

2B11D11

Cat no : 66248-1-Ig

Synonyms

B7 H, B7 H1, B7 homolog 1, B7H1, CD274, CD274 molecule, PD L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, PD-L1, PD-L1/CD274, Programmed death ligand 1



Tested Applications

Positive WB detected inA375 cells, human placenta tissue, pig lung tissue, human skeletal muscle tissue, HepG2 cells, THP-1 cells, RAW 264.7 cells, A549 cells, K-562 cells, HSC-T6 cells
Positive IHC detected inhuman tonsillitis tissue, mouse heart tissue, human placenta tissue, human heart tissue, human lung cancer tissue

Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive IF detected inHeLa cells
Positive FC detected inRaji cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:2000-1:10000
Immunohistochemistry (IHC)IHC : 1:5000-1:20000
Immunofluorescence (IF)IF : 1:50-1:500
Sample-dependent, check data in validation data gallery

Product Information

66248-1-Ig targets PD-L1/CD274 in FC, IF, IHC, WB, ELISA applications and shows reactivity with human, mouse, pig, rat samples.

Reactivity human, mouse, pig, rat
Cited Species human, mouse
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Immunogen PD-L1/CD274 fusion protein Ag12443
Full Name CD274 molecule
Calculated molecular weight 290aa,33 kDa
Observed molecular weight 45-50 kDa
GenBank accession number BC074984
Gene symbol CD274
Gene ID (NCBI) 29126
Conjugate Unconjugated
Form Liquid
Purification Method Protein G purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20oC. Aliquoting is unnecessary for -20oC storage.

Background Information

PD-L1, also known as CD274 or B7H1, stands for programmed cell death ligand 1. It is a type I transmembrane protein that is thought to repress immune responses by binding to its receptor (PD1), thus inhibiting T-cell activation, proliferation, and cytokine production. It contains V-like and C-like immunoglobulin domains. PD-L1 expression is regulated by various cytokines, such as TNF-α or LPS (ISSN: 1848-7718). Increased expression of this protein in certain types of cancers, e.g., renal cell carcinoma or colon cancer, correlates with poor prognosis. 

What is the molecular weight of PD-L1? 

Depending on the isoform, the calculated molecular weight of the protein varies between 20 and 33 kDa (176–290 aa). 

What are the isoforms of PD-L1? 

According to NCBI, three different isoforms have been identified. There are significant differences in the untranslated and protein coding regions. 

What is the subcellular localization and tissue specificity of PD-L1? 

It is predicted to localize in the plasma membrane of various cell types, with a particularly high expression in placental trophoblast and subsets of immune cells. High levels of PD-L1 protein have also been detected in lung and colon tissues. 

What is the function of PD-L1 in immune responses? 

PD-L1 is critical for the induction and maintenance of immune self-tolerance during infection or inflammation in normal tissues. The interaction of PD-L1 and its receptors is responsible for preventing auto-immune phenotypes and balancing the overall immune response in situations such as pregnancy or tissue allografts. The interaction between PD-L1 and PD-1 or B7.1 starts an inhibitory signaling cascade, which results in the decreased proliferation of antigen-specific T-cells and increased survival of regulatory T-cells (PMID: 15240681). 

How can PD-L1’s implication in cancer be used as a drug target? 

In certain tumors, high expression of PD-L1 serves as a stop-sign to inhibit the recognition of cancer cells by T-cells (PMID: 23087408). The interaction between PD-L1 and its receptors (PD1 and B7.1) is a mechanism for the tumor to evade the host immune response (PMID: 29357948). Several mAbs have been developed to target that interaction and thus prevent the inactivation of cytotoxic T-cells by the tumor (PMIDs: 23890059, 18173375).


Protocols

Product Specific Protocols
WB protocol for PD-L1/CD274 antibody 66248-1-IgDownload protocol
IHC protocol for PD-L1/CD274 antibody 66248-1-IgDownload protocol
IF protocol for PD-L1/CD274 antibody 66248-1-IgDownload protocol
FC protocol for PD-L1/CD274 antibody 66248-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
mouseIHC

Antiviral Res

Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection.

Authors - Tianying Wang
humanIHC

Front Oncol

PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival.

Authors - Shaochuan Liu
humanWB

J Immunol

FGFR2 Promotes Expression of PD-L1 in Colorectal Cancer via the JAK/STAT3 Signaling Pathway.

Authors - Piao Li
humanIHC

Otolaryngol Head Neck Surg

PD-L1 Expression and Tumor-Infiltrating Lymphocytes in High-Risk and Metastatic Cutaneous Squamous Cell Carcinoma.

Authors - Misha Amoils
humanIHC

JAAD Case Rep

A case of metastatic basal cell carcinoma treated with continuous PD-1 inhibitor exposure even after subsequent initiation of radiotherapy and surgery.

Authors - John G D Cannon
human,mouseWB

Biochim Biophys Acta Mol Basis Dis

MLL3 enhances the transcription of PD-L1 and regulates anti-tumor immunity.

Authors - Wei Xiong